Dr. Daryl Davies speaking October 20 for KSOM- live and on webcast

Keck School of Medicine of USC Research Seminar Series presents

“A Multi- Pronged Approach for Developing Novel Therapeutic Agents for Alcohol Use Disorders”

 Daryl L. Davies, PhD Associate Professor of Clinical Pharmacy, School of Pharmacy, University of Southern California


Date: Monday, October 20, 2014

Time: 12:00 pm – 1:00 pm

Note: A light lunch will be served before the seminar at 11:30 am

Location: Aresty Auditorium, NRT, LG

Webcast: http://keckmedia.usc.edu/Mediasite/Catalog/catalogs/keck-research-seminar


Using a cross-disciplinary approach, our group has established that ivermectin (IVM), is an effective pharmacotherapeutic agent able to reduce alcohol consumption and preference in rodent models. Moreover, building evidence indicates that P2X4 receptors (P2X4Rs) play an important role in IVM’s anti-alcohol effects. As IVM is currently FDA-approved and used by millions of humans each year, its successful development as a new pharmacological approach to reduce alcohol consumption would open exciting new arena in the search for new drugs to treat alcohol use disorders (AUDs). Dr. Davies will discuss a multi-pronged approach aimed at rapidly developing IVM as a new indication (i.e., repurposing) and/or chemically optimizing IVM (i.e., using IVM as a platform) for treating AUDs. This presentation will include: 1) Recent investigations of structure-activity relationships that support a pro-drug strategy for increasing CNS availability of IVM based on in vitro and preclinical studies; 2) updates on a joint USC/UCLA Clinical and Translational Science Institute sponsored effort that focuses on repurposing IVM for the treatment of AUDs in alcohol dependent individuals 3) recent in vitro electrophysiological studies and in vivo studies using P2X4 knock-out mice and shRNA techniques suggesting that P2X4R positive allosteric modulators represent a new class of compounds for the treatment of AUDs.